MOMENTUS Biopharma's AI Launch, $230M AmacaThera Deal, and More - Life AI Weekly #41

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in AI within the healthcare and life sciences sectors. This week, we spotlight several significant developments, including the launch of MOMENTUS Biopharma Consulting, which aims to leverage AI in healthcare. Additionally, AmacaThera and Pacira BioSciences have entered a substantial $230 million deal focused on AI-driven drug delivery solutions.

In the biotech arena, Expert.ai has introduced new AI solutions at BioTechX Europe 2025, while Fosun International continues to innovate with AI and drug developments. Meanwhile, Metagenomi is cutting AI costs by utilizing AWS Inferentia 2. These stories highlight the dynamic intersection of AI and healthcare, showcasing how technology is reshaping the industry landscape.

ExaCare AI has secured $30 million in Series A funding to enhance its AI platform for skilled nursing facilities, focusing on improving admissions and reducing administrative tasks. Meanwhile, Archy has raised $20 million in Series B funding to automate scheduling and payments in dental practices, aiming to save significant time for practitioners.

MOMENTUS Biopharma Consulting has been launched by Scott Roberts and John 'Zeke' Czekanski to leverage AI for integrated healthcare solutions.
AmacaThera and Pacira BioSciences have entered a $230 million licensing agreement to advance AI-driven drug delivery technologies, enhancing therapeutic solutions.

MOMENTUS Biopharma Consulting launched to leverage AI in healthcare, aiming to enhance drug discovery and development processes. Meanwhile, AmacaThera and Pacira BioSciences signed a $230 million deal to advance AI-driven drug delivery systems.

Expert.ai has introduced new AI solutions to improve research and regulatory processes in the pharmaceutical and life sciences industries, unveiled at BioTechX Europe 2025.
Fosun International is enhancing global healthcare with AI-driven solutions and innovative drug developments, including the anti-PD-1 monoclonal antibody HANSIZHUANG for small cell lung cancer, approved in nearly 40 countries.
Metagenomi reduced its AI costs by 56% by switching from Nvidia GPUs to AWS' Inferentia 2 accelerators, utilizing generative AI models for enzyme discovery.

SYNERGEN Health has partnered with Lighthouse Lab Services to enhance revenue cycle management for laboratories using AI-driven technology. Meanwhile, Biocare Medical and Hamamatsu have announced a strategic collaboration to advance spatial biology solutions, leveraging their combined expertise to push forward research and development in the field.